



TYPE 1 DIABETES TRIALNET



Benaroya Research Institute (BRI) is the clinical network hub of Type 1 Diabetes (T1D) TrialNet, an international collaboration of the world’s leading researchers in type 1 diabetes for more than 20 years. TrialNet explores ways to prevent, delay and slow progression of the disease in families over time.

FUNDED BY NIH

TrialNet is supported by National Institutes of Health (NIH), the nation’s medical research agency, along with the National Institutes of Diabetes and Digestive and Kidney Diseases, JDRF, American Diabetes Association, and Helmsley Charitable Trust.

PROGRAM CHAIR



Carla J. Greenbaum, MD
Diabetes Research Program Director
BRI Clinical Research Center Director

How TrialNet Helps Those with T1D

Many people with type 1 diabetes are still producing small amounts of insulin at the time of diagnosis. TrialNet looks for treatments that can help extend insulin production since even small amounts of natural insulin production can decrease long-term complications and improve disease management.

For relatives of people with type 1 diabetes — who are at 15 times the risk of developing the disease — TrialNet offers a unique risk screening test that can identify those persons with the highest risk years before symptoms appear.

4 / 200+

Clinical and prevention studies

Clinical sites

156+ THOUSAND

Individuals screened for T1D

226+ THOUSAND

Blood samples processed

PROGRESS TO PREDICT, DELAY, & PREVENT T1D

Help for the newly diagnosed

TrialNet researchers are currently testing whether a drug used alone or in combination with another drug will help those newly diagnosed (within the last three months) continue to make some of their own insulin.

A pilot study found that those who received the combination maintained insulin production for up to one year after treatment compared to the untreated group who experienced a nearly 40 percent decline.

Prevention studies

Based on screening results, individuals may be eligible to join one of three prevention studies. Each study tests a medication — oral insulin, abatacept and teplizumab — to see if the drug can help delay and/or prevent onset of type 1 diabetes. All of the medications have shown promise in earlier clinical studies.

JOIN US

Benaroya Research Institute at Virginia Mason (BRI) is an independent, nonprofit biomedical research institute with a focus on understanding diseases of the immune system. A leader of collaborative initiatives such as the [Immune Tolerance Network](#) and [Type 1 Diabetes TrialNet](#), BRI frequently partners with global research institutes, pharmaceutical and biotech companies.

Get More Information

Visit BenaroyaResearch.org and sign up to receive research updates.

Follow stories on the Autoimmune Life blog at BenaroyaResearch.org/blog

Follow us



Partner in Discovery

We need volunteer donors with and without disease.

BRI researchers work with hundreds of physicians and patients through biorepositories and clinical trials—all focused on improving human health.

Register to donate to a biorepository at BenaroyaResearch.org/bio

Donate

To support lifesaving medical research visit: BenaroyaResearch.org/donate-now

